Beit Jala Pharmaceutical Company Announces Audited Earnings Results for the Year Ended December 31, 2017
Beit Jala Pharmaceutical Company announced audited earnings results for the year ended December 31, 2017. For the year, the company reported sales of JOD 8,323,963 against JOD 7,819,715 a year ago. Net income before tax was JOD 1,781,456 against JOD 2,067,095 a year ago. Net income after tax was JOD 1,645,697 against JOD 1,924,748 a year ago. Basic and diluted earnings per share were JOD 0.235 against JOD 0.275 a year ago. Net cash flow from operating activities was JOD 2,552,990 against JOD 3,019,557 a year ago. Purchase of property, plant and equipment was JOD 982,524 against JOD 1,959,969 a year ago.